Communiqués MedMira Inc. OTC Markets

Actions

Marché Fermé - OTC Markets Autres places de cotation 21:39:42 21/06/2024			Varia. 5j.	Varia. 1 janv.
0,0866 ^USD	+561,07%		-.--%	+29,45%

02/04	MedMira Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 janvier 2024	CI
27/03	Samsung Pay ne fonctionnera plus avec le système de paiement russe Mir à partir du 3 avril	RE

Canadian Investment Regulatory Organization Trade Resumption - MIR	31/08/23	AQ
Canadian Investment Regulatory Organization Trading Halt - MIR	29/08/23	AQ
MedMira enters into Partnership with Maternova for USA and Latin America	21/02/23	AQ
MedMira provides Progress Update	03/10/22	EQ
MedMira provides Progress Update	03/10/22	AQ
MedMira Strengthens and Expands Board	15/07/22	AQ
MedMira Reports Third Quarter Results FY2022	30/06/22	AQ
MedMira Receives Patent for its Unique Quantitative Diagnostic System	06/06/22	AQ
MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market	27/05/22	AQ
VYRA™ Product Line Update	20/05/22	GL
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test	12/05/22	GL
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test	12/05/22	GL
MedMira receives the CE mark for its Reveal TP (Syphilis) and starts clinical trials in Canada	10/03/22	AQ
MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada	09/03/22	AQ
MedMira Receives CE Marking for its REVEALCOVID-19 PLUS Total Antibody Test	09/02/22	AQ
MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test	09/02/22	AQ
MedMira Provides a Pre-Annual General Meeting Update	04/02/22	AQ
MedMira Reports First Quarter Results FY2022	31/12/21	AQ
MedMira Announces VYRA™ CoV2Flu and Additional Regulatory Opportunities	22/12/21	AQ
MedMira strengthen its Board with New Appointment	17/12/21	AQ

Aucun résultat pour cette recherche